Syneos Health

Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Syneos Health reports mixed Q4 results, focuses on growth strategies

Syneos Health's Q4 performance showed mixed results with revenue decline but growth on a constant currency basis. The company is focused on enhancing its operating model, customer engagement, and winning new business opportunities.
Challenges include evaluating spending by large pharma customers and the need for cost structure realignment. However, opportunities lie in engaging with analysts, driving cost savings, and expecting larger pharma awards in 2023.
Overall, Syneos Health remains confident in its strategy, investments, and ability to drive growth in Clinical. The company is navigating challenges while leveraging strengths in customer relationships and value-based pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

MORRISVILLE, N.C., June 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation (the “Selling Stockholders”) of an aggregate of 10,851,676 shares of the Company's common stock (the “Offering”). Syneos Health is not selling any shares and will not receive any proceeds from the proposed sale of the shares by the Selling Stockholders in the Offering. The Offering is expected to close on June 7, 2021, subject to customary closing conditions.

Syneos Health Announces Pricing of Secondary Offering of Common Stock

MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced it commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation (the “Selling Stockholders”) of an aggregate of 10,851,676 shares of the Company's common stock (the “Offering”) pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission (“SEC”). Syneos Health is not selling any shares and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the Offering.

Syneos Health Announces Secondary Offering of Common Stock

Syneos Health saw its share price increase by about 25% since my previous article, and I missed the boat as my limit order didn't get hit. Despite the strong recent performance, Syneos still isn't expensive as it's performing slightly ahead of expectations.

Syneos Health: Up 25%, But There's Room For Additional Growth

Syneos Health, Inc. (SYNH) CEO Alistair Macdonald on Q1 2021 Results - Earnings Call Transcript

MORRISVILLE, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- The Illingworth Research Group, a Syneos Health® company, has been recognized with a 2021 Queen's Award for Enterprise for International Trade. Illingworth Research Group™ is a leading global provider of clinical research home health services. With healthcare already becoming more local, COVID-19 has accelerated the need for in-home clinical trial services which have realized increasing demand in recent years.

Illingworth Research Group Recognized with Queen's Award for Enterprise: International Trade 2021

Syneos Health (SYNH) delivered earnings and revenue surprises of 6.76% and 1.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Tops Q1 Earnings and Revenue Estimates

Shares of Syneos Health (NASDAQ:SYNH) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share increased 16.18% over the past year to $0.79, which beat the estimate of $0.75.

Recap: Syneos Health Q1 Earnings

Syneos Health Reports First Quarter 2021 Results

MORRISVILLE, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its first quarter 2021 financial results on Thursday, April 29, 2021, prior to its earnings call at 8:00 a.m. ET.

Syneos Health Schedules First Quarter 2021 Earnings Call for Thursday, April 29, 2021

Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.

Reasons to Hold on to Syneos Health (SYNH) Stock For Now

Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.

Syneos Health (SYNH) New Partnership to Enhance Clinical Trials

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock?

Why Is Syneos Health (SYNH) Up 4.1% Since Last Earnings Report?

Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review

Syneos Health and Protocol First Partner to Accelerate Collection and Review of Clinical Trial Data

Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy

Syneos Health Communications Bolsters Value, Access and Public Affairs Offerings with Key Senior Hires

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

Syneos Health (SYNH) Posts In-Line Q4 Earnings, Margins Up

Syneos Health, Inc. (SYNH) CEO Alistair Macdonald on Q4 2020 Results - Earnings Call Transcript

Syneos Health (SYNH) delivered earnings and revenue surprises of 0.00% and 0.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Matches Q4 Earnings Estimates

Shares of Syneos Health (NASDAQ:SYNH) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 7.77% year over year to $1.11, which beat the estimate of $1.10.

Syneos Health: Q4 Earnings Insights

Syneos Health Reports Fourth Quarter and Full Year 2020 Results

Shared Commitment to Change, New Prescriber Realities, Model Evolution and Engagement Transformation Expected to be Critical Drivers Shared Commitment to Change, New Prescriber Realities, Model Evolution and Engagement Transformation Expected to be Critical Drivers

Syneos Health Identifies Important Drivers of Change Expected to Disrupt Healthcare

MORRISVILLE, N.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2020 financial results on Thursday, February 18, 2021, prior to its earnings call at 8:00 a.m. ET.

Syneos Health Schedules Fourth Quarter and Full Year 2020 Earnings Call for Thursday, February 18, 2021

MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 a.m. EST.

Syneos Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.

Syneos Health (SYNH) Buys Illingworth Research, Expands CRO Base

Acquisition Enhances Company's Decentralized Solutions Offering by Strengthening Patient Focus Acquisition Enhances Company's Decentralized Solutions Offering by Strengthening Patient Focus

Syneos Health Acquires Illingworth Research Group, a Leading Provider of Clinical Research Home Health Services

As of late, it has definitely been a great time to be an investor in Syneos Health (SYNH).

News for Syneos Health Stock (SYNH)